CLYYF (Celyad Oncology) FFO per Share


CLYYF Celyad Oncology SA CLYYF
13 GF Score
Price $0.25
GF Value $0.46
! 6 Warning Signs
View Full Analysis

What is Celyad Oncology FFO per Share?

FFO per Share only applies to REITs.

CLYYF
13GF Score
Celyad Oncology SA CLYYF
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celyad Oncology (CLYYF) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued. The current stock price of $0.25 is trading 45.7% below its estimated GF Value™ of $0.46.

Key valuation signals for CLYYF:

  • FFO per Share:
  • GF Value™: $0.46 vs. price of $0.25 (45.7% below fair value)
  • GF Score™: 13/100 with 6 warning signs

No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celyad Oncology Business Description

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
13GF Score

Get the complete analysis for CLYYF

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.46
GF Value